Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy
2018 StandoutNobel
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
2016
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
2014
ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program
2015
Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression
2021 StandoutNobel
T-cell exhaustion in the tumor microenvironment
2015
Graft microvascular disease in solid organ transplantation
2014 StandoutNobel
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Current knowledge on exosome biogenesis and release
2017 Standout
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study
2015
Molecular screening of cancer-derived exosomes by surface plasmon resonance spectroscopy
2015
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
2023 StandoutNobel
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
2019
Engineering precision nanoparticles for drug delivery
2020 Standout
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
2022 StandoutNobel
Harnessing the immune system for the treatment of breast cancer
2014
QuPath: Open source software for digital pathology image analysis
2017 Standout
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
2015
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
2015
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
2019
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
Natural and therapy-induced immunosurveillance in breast cancer
2015
The immune contexture in cancer prognosis and treatment
2017 Standout
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
2015
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
2014
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Checkpoint inhibitors in breast cancer – Current status
2017
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
2015
Overcoming T cell exhaustion in infection and cancer
2015
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
2022 StandoutNobel
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Antagonists of PD-1 and PD-L1 in Cancer Treatment
2015
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Immunotherapy for Breast Cancer: Current and Future Strategies
2017
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
2017
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
2018
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
2014
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Molecular and cellular insights into T cell exhaustion
2015 Standout
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB
2017
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
2014
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
2015
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
2021
ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori
2016 StandoutNobel
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Immune targeting in breast cancer.
2015
Nanovaccines for cancer immunotherapy
2019
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Prognostic and predictive value of PDL1 expression in breast cancer
2014
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
2018
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
2014
CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
2016
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes
2015
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
2015
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
2015
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis
2017
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
2019
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
2018
Works of W.E. Gillanders being referenced
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
2013
EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer
2013
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
2014
Preclinical and clinical development of neoantigen vaccines
2017